Background: The Verify-Now system can evalua teplatelet reactivity results in minutes, providing antiplatelet therapy guidance in many clinical settings. Understanding the patient´s unique response to antiplatelet drugs is important for making effective treatment decisions.

Aims: To evaluate the effectiveness and safety of antiplatelet therapy in patients receiving antiplatelet therapy.

Methods: A retrospective analysis of the evaluation of residual platelet reactivity (ORT) of P2Y12 PRU and ARU by bedside aggregatometry using the Verify-Now system was performed in 170 patients admitted with a diagnosis of coronary heart disease.

Results: We examined 115 a men and 55 a women mediana (Me) age 64 years who received aspirin and/or clopidogrel, ticagrelol. At 116 patients received aspirin therapy the ARU index was Me 400 (95% 423.9; 457.5) units. Clopidogrel therapy was assigned at 133 patients, 27 patients received ticagrelor, form them 79 received DAT. Indicator PRU of the clopidogrel therapy has made Me 126 (83.4; 178,4). ORT for plavix was Me 99 (89,9; 131,4), for zilt – Me 190.0 (160.8; 215.1), for ticagrelor – Me 17.0 (2.23; 149) Stroke (24.7%), thrombosis stent (11.8%), bleeding (11.2%), unstable angina (15.3%), recurrent ACS (27.1%) and were indications for the ORT analysis. Thrombosis stent developed on the therapy of P2Y12 inhibitor (original plavix, n=9) PRU made Me 105.4 (92.5; 136.1), Me 17.0 (2.23; 149) of the reception of generic clopidogrel (n=8), ticagrelor (n=3), which indicated low compliance of therapy and required pharmacogenetics analysis.

Conclusions: Cases of resistance to antiplatelet drugs and compliance problems can lead to a recurrence of vascular events and to create schools for patients receiving antiplatelet drugs.

« Back to ISTH 2020 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/monitoring-the-safety-and-effectiveness-of-antiplatelet-therapy/